We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Vaccine, therapy, plasma, 【초록키워드】 public health, Vaccines, antibody, Immunotherapy, COVID-19 pandemic, monoclonal antibody, Infection, virus, receptor, recovered patients, S-protein, infected patients, clinician, enzyme, benefit, event, antibody-based therapy, virus-neutralizing antibody, ENhance, PROTECT, form, the antibody response, SARS-CoV-2-infected patient, 【제목키워드】 immunization, therapeutic,